Meeder Asset Management’s Avalo Therapeutics AVTX Stock Holding History

Meeder Asset Management’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Hold	0	–	-$7	–	471
2023 Q3	–	Hold	0	–	–	–	484
2023 Q2	–	Hold	0	–	–	–	500
2023 Q1	–	Sell	-6	Closed	-$4.73K	–	582
2022 Q4	$7.59K	Hold	6	–	–	﹤0.01%	667
2022 Q3	$5K	Hold	6	–	–	﹤0.01%	1537
2022 Q2	$9K	Hold	6	–	–	﹤0.01%	1398
2022 Q1	$13K	Buy	+6	New	+$15.1K	﹤0.01%	1443
2021 Q4	–	Sell	-7	Closed	-$43K	–	1245
2021 Q3	$43K	Hold	7	–	–	﹤0.01%	1136
2021 Q2	$64K	Buy	7 +4	+133%	+$33.5K	﹤0.01%	1045
2021 Q1	$31K	Buy	+3	New	+$28.3K	﹤0.01%	1265
2020 Q4	–	Sell	-2	Closed	-$10K	–	1882
2020 Q3	$10K	Hold	2	–	–	﹤0.01%	1365
2020 Q2	$12K	Hold	2	–	–	﹤0.01%	1257
2020 Q1	$11K	Hold	2	–	–	﹤0.01%	1461
2019 Q4	$29K	Hold	2	–	–	﹤0.01%	1225
2019 Q3	$22K	Buy	+2	New	+$22.3K	﹤0.01%	1266

Other funds holding AVTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Meeder Asset Management's AVTX Position: Q4 2023 in Review

Meeder Asset Management held its Avalo Therapeutics (AVTX) position steady in Q4 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #471.

Meeder Asset Management first reported a position in AVTX in Q3 2019 and has held it in 12 quarters since. The position peaked at $64K in Q2 2021. 12 funds tracked by Wall St. Rank hold AVTX as of Q4 2023.

Meeder Asset Management held 0 shares of Avalo Therapeutics worth $0 as of Q4 2023.
Meeder Asset Management left its Avalo Therapeutics share count unchanged in Q4 2023.
Avalo Therapeutics made up ﹤0.01% of Meeder Asset Management's portfolio in Q4 2023, its #471 holding.
Meeder Asset Management first reported a position in Avalo Therapeutics in Q3 2019 and has held it in 12 quarters since.
Meeder Asset Management's Avalo Therapeutics position peaked at $64K in Q2 2021.
12 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2023.

Based on Meeder Asset Management's 13F filing for Q4 2023, filed 25 Jan 2024.